Development of Composite Sponge Scaffolds Based on Carrageenan (CRG) and Cerium Oxide Nanoparticles (CeO 2 NPs) for Hemostatic Applications
Alizadeh K., Dezvare Y., Kamyab S., Amirian J., Brangule A., Bandere D.
Laboratory Study, published in Biomimetics (Basel) (2023) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Biomimetics (Basel) (2023)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 37754160
- PMCID
- PMC10527261
- DOI
- 10.3390/biomimetics8050409
- Citations
- 5
Abstract (original English)
In this study, a novel absorbable hemostatic agent was developed using carrageenan (CRG) as a natural polymer and cerium oxide nanoparticles (CeO 2 NPs). CRG-CeO 2 -0.5 and CRG-CeO 2 -1 composites were prepared by compositing CeO 2 to CRG + CeO 2 at a weight ratio of 0.5:100 and 1:100, respectively. The physicochemical and structural properties of these compounds were studied and compared with pristine CRG. Upon incorporation of CeO 2 nanoparticles into the CRG matrix, significant reductions in hydrogel degradation were observed. In addition, it was noted that CRG-CeO 2 exhibited better antibacterial and hemostatic properties than CRG hydrogel without CeO 2 NPs. The biocompatibility of the materials was tested using the NIH 3T3 cell line, and all samples were found to be nontoxic. Particularly, CRG-CeO 2 -1 demonstrated superior hemostatic effects, biocompatibility, and a lower degradation rate since more CeO 2 NPs were present in the CRG matrix. Therefore, CRG-CeO 2 -1 has the potential to be used as a hemostatic agent and wound dressing.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.